PMC:7534795 / 45202-45481 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T205","span":{"begin":58,"end":68},"obj":"Body_part"},{"id":"T206","span":{"begin":173,"end":181},"obj":"Body_part"}],"attributes":[{"id":"A205","pred":"fma_id","subj":"T205","obj":"http://purl.org/sig/ont/fma/fma82738"},{"id":"A206","pred":"fma_id","subj":"T206","obj":"http://purl.org/sig/ont/fma/fma85272"}],"text":"ly (NCT04311177, 2020)\n• Eicosapentaenoic acid (EPA) free fatty acid for hospitalized COVID-19 patients • Phase 3 interventional trial\n• Treatment with EPA gastro-resistant capsules vs. standard care\n• 28-day treatment period\n• Primary outcome of time to treatment failure i.e. n"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T335","span":{"begin":86,"end":94},"obj":"Disease"}],"attributes":[{"id":"A335","pred":"mondo_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ly (NCT04311177, 2020)\n• Eicosapentaenoic acid (EPA) free fatty acid for hospitalized COVID-19 patients • Phase 3 interventional trial\n• Treatment with EPA gastro-resistant capsules vs. standard care\n• 28-day treatment period\n• Primary outcome of time to treatment failure i.e. n"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T349","span":{"begin":25,"end":46},"obj":"Chemical"},{"id":"T350","span":{"begin":42,"end":46},"obj":"Chemical"},{"id":"T351","span":{"begin":48,"end":51},"obj":"Chemical"},{"id":"T353","span":{"begin":58,"end":68},"obj":"Chemical"},{"id":"T354","span":{"begin":64,"end":68},"obj":"Chemical"},{"id":"T355","span":{"begin":152,"end":155},"obj":"Chemical"}],"attributes":[{"id":"A349","pred":"chebi_id","subj":"T349","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A350","pred":"chebi_id","subj":"T350","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A351","pred":"chebi_id","subj":"T351","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A352","pred":"chebi_id","subj":"T351","obj":"http://purl.obolibrary.org/obo/CHEBI_36006"},{"id":"A353","pred":"chebi_id","subj":"T353","obj":"http://purl.obolibrary.org/obo/CHEBI_35366"},{"id":"A354","pred":"chebi_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A355","pred":"chebi_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A356","pred":"chebi_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/CHEBI_36006"}],"text":"ly (NCT04311177, 2020)\n• Eicosapentaenoic acid (EPA) free fatty acid for hospitalized COVID-19 patients • Phase 3 interventional trial\n• Treatment with EPA gastro-resistant capsules vs. standard care\n• 28-day treatment period\n• Primary outcome of time to treatment failure i.e. n"}

{"project":"LitCovid-sentences","denotations":[{"id":"T385","span":{"begin":23,"end":134},"obj":"Sentence"},{"id":"T386","span":{"begin":135,"end":199},"obj":"Sentence"},{"id":"T387","span":{"begin":200,"end":225},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ly (NCT04311177, 2020)\n• Eicosapentaenoic acid (EPA) free fatty acid for hospitalized COVID-19 patients • Phase 3 interventional trial\n• Treatment with EPA gastro-resistant capsules vs. standard care\n• 28-day treatment period\n• Primary outcome of time to treatment failure i.e. n"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1315","span":{"begin":95,"end":103},"obj":"Species"},{"id":"1355","span":{"begin":86,"end":94},"obj":"Disease"}],"attributes":[{"id":"A1315","pred":"tao:has_database_id","subj":"1315","obj":"Tax:9606"},{"id":"A1355","pred":"tao:has_database_id","subj":"1355","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ly (NCT04311177, 2020)\n• Eicosapentaenoic acid (EPA) free fatty acid for hospitalized COVID-19 patients • Phase 3 interventional trial\n• Treatment with EPA gastro-resistant capsules vs. standard care\n• 28-day treatment period\n• Primary outcome of time to treatment failure i.e. n"}